3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[d]咪唑-1-基)-2-噻吩甲酰胺
![3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[d]咪唑-1-基)-2-噻吩甲酰胺结构式](https://image.chemsrc.com/caspic/437/660868-91-7.png)
3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[d]咪唑-1-基)-2-噻吩甲酰胺结构式
|
常用名 | 3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[d]咪唑-1-基)-2-噻吩甲酰胺 | 英文名 | GW843682X |
|---|---|---|---|---|
| CAS号 | 660868-91-7 | 分子量 | 477.46 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 629.6±65.0 °C at 760 mmHg | |
| 分子式 | C22H18F3N3O4S | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 334.6±34.3 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Cell Cycle 14(3) , 399-407, (2015) The mechanistic target of rapamycin complex 1 (mTORC1) increases translation, cell size and angiogenesis, and inhibits autophagy. mTORC1 is negatively regulated by hamartin and tuberin, the protein products of the tumor suppressors TSC1 and TSC2 that are muta... |
|
|
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Mol. Cancer Ther. 6 , 450-459, (2007) Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have... |
期刊文献综述：
更多...